RPCONE
RUBY

Retirement Planning Company of New England’s Rubius Therapeutics, Inc RUBY Stock Holding History

Retirement Planning Company of New England’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-20
Closed – – 966
2021
Q4 		$0 Buy
+20
New +$277 ﹤0.01% 979

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFM
Abbot Financial Management Andover, Massachusetts $293M AUM 36.12% 1-Year Est. Return

Retirement Planning Company of New England's RUBY Position: Q1 2022 in Review

Retirement Planning Company of New England sold out of Rubius Therapeutics, Inc (RUBY) in Q1 2022, closing a stake of 20 shares.

Retirement Planning Company of New England first reported a position in RUBY in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 117 funds tracked by Wall St. Rank hold RUBY as of Q1 2022.

  • Retirement Planning Company of New England reported no remaining Rubius Therapeutics, Inc position as of Q1 2022 after selling out during the quarter.
  • Retirement Planning Company of New England sold 20 Rubius Therapeutics, Inc shares in Q1 2022.
  • Retirement Planning Company of New England first reported a position in Rubius Therapeutics, Inc in Q4 2021 and held it in 1 quarter.
  • Retirement Planning Company of New England's Rubius Therapeutics, Inc position peaked at $0 in Q4 2021.
  • 117 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2022.

Based on Retirement Planning Company of New England's 13F filing for Q1 2022, filed 6 May 2022.